|Slideshows|March 2, 2018

10 Factors to Consider When Assessing PTSD

The author addresses some of the complexities in assessing and managing treatment-resistant PTSD.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

FDA Grants De Novo Approval to Modius Spero, Neuromodulation Device for PTSD

ByLeah Kuntz

May 26th 2026

Childbirth-Related PTSD: Recognizing and Assessing This Unique Subtype

ByAmanda Koire, MD, PhD

May 18th 2026

Intimate Partner Violence and Psychiatric Leadership: Clinical Perspectives

ByJames Rachal, MD

May 16th 2026

FDA Fast-Tracks Psychedelic Therapies for Depression, PTSD, and Alcohol Use Disorder

ByHeidi Anne Duerr, MPH

April 24th 2026

Multilayered Trauma, One PTSD Diagnosis?

ByErica Browne,Catalina Belean, MD

March 9th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

10 Factors to Consider When Assessing PTSD

Related Content

FDA Grants De Novo Approval to Modius Spero, Neuromodulation Device for PTSD

Childbirth-Related PTSD: Recognizing and Assessing This Unique Subtype

Intimate Partner Violence and Psychiatric Leadership: Clinical Perspectives

FDA Fast-Tracks Psychedelic Therapies for Depression, PTSD, and Alcohol Use Disorder

Multilayered Trauma, One PTSD Diagnosis?

Latest CME

Southern California Psychiatry Conference

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Trending on Psychiatric Times

FDA Issues CRL for CTx-1301 for Treatment of ADHD

Insights Into Mechanism-Based Biomarkers for Psychosis Prediction from Kim Do, PhD

New Name, New Path for Psychiatry: The Future of the DSM

Nonpharmacological Augmentation of Ketamine, Neuroplasticity, and Behavioral Therapy

Endangered Education: Psychiatric Professional Degrees Under Attack